United TherapeuticsUTHR -1.66%85 Net Current Asset Value is $48.84 as of Mar. 2026, which is 767% above its 10-year median of 5.63. GuruFocus rates UTHR with a GF Score™ of 85/100 and a GF Value™ of $386.86 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 610 Drug Manufacturers companies, United Therapeutics ranks worse than 74.59% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
United Therapeutics's net current asset value per share for the quarter that ended in Mar. 2026 was $48.84.
The historical rank and industry rank for United Therapeutics's Net Current Asset Value or its related term are showing as below:
UTHR'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.11 Med: 5.63 Max: 12.14
Current: 11.35
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of United Therapeutics was 12.14. The lowest was 4.11. And the median was 5.63.
UTHR's Price-to-Net-Current-Asset-Value is ranked worse than 74.59% of 610
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs UTHR: 11.35
United Therapeutics (NAS:UTHR) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
United Therapeutics Net Current Asset Value Related Terms
United Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for United Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UTHR vs VTRS, NBIX, ZTS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $48.84 mean?
United Therapeutics (UTHR) has a Net Current Asset Value of $48.84 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on United Therapeutics and its competitors. This is 767% above median its historical median of 5.63. Over the past decade, United Therapeutics' Net Current Asset Value has ranged from 4.11 to 12.14. According to the industry distribution chart, United Therapeutics ranks #455 out of 610 companies in the Drug Manufacturers industry, placing it in the top 74.6%.
Is United Therapeutics' Net Current Asset Value too high?
United Therapeutics' current Net Current Asset Value of $48.84 is 767% above median its 10-year median of 5.63. Over the past 10 years, this metric has ranged from a low of 4.11 to a high of 12.14. The Drug Manufacturers industry median Net Current Asset Value is 5.69. United Therapeutics' value of $48.84 is 758.3% above this industry median. Based on the distribution chart, United Therapeutics ranks #455 out of 610 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, United Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Net Current Asset Value compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #455 out of 610 companies for Net Current Asset Value. This places United Therapeutics in the lower half of its industry. The industry median Net Current Asset Value is 5.69. United Therapeutics' value of $48.84 is 758.3% above this benchmark. Historically, United Therapeutics' own Net Current Asset Value has ranged from 4.11 to 12.14 over the past decade. While the company's 10-year median is 5.63 vs. the industry median of 5.69, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.69, based on 610 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current Net Current Asset Value of $48.84 is 758.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current Net Current Asset Value is $48.84, which is 767% above median its own 10-year median of 5.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.86, compared to a current price of $554.37 — trading 43.3% above its estimated fair value. The current Net Current Asset Value is $48.84, which is 767% above median its 10-year median of 5.63 and 758.3% above the Drug Manufacturers industry median of 5.69. United Therapeutics' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Net Current Asset Value is $48.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $554.37 is trading 43.3% above its estimated GF Value™ of $386.86.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
Net Current Asset Value: $48.84 (767% above median its 10-year median of 5.63)
GF Value™: $386.86 vs. price of $554.37 (43.3% above fair value)
Industry Position: 758.3% above the Drug Manufacturers median (#455 of 610)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
85GF Score
Get the complete analysis for UTHR
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
